Overview
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease
Status:
Completed
Completed
Trial end date:
2005-11-01
2005-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for advanced Hodgkin's disease. PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens in treating patients with advanced Hodgkin's disease.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Medical Research CouncilTreatments:
Bleomycin
Chlorambucil
Dacarbazine
Doxorubicin
Etoposide
Liposomal doxorubicin
Prednisolone
Procarbazine
Vinblastine
Vincristine
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed advanced Hodgkin's disease requiringsystemic therapy Stage IA or IIA disease with bulky disease or more than three sites of
involvement are also eligible
PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified
Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other
active malignancy within 5 years HIV negative Not pregnant or nursing Fertile patients must
use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy for Hodgkin's disease Endocrine therapy: Not specified Radiotherapy: No prior
radiotherapy for Hodgkin's disease Surgery: Not specified